Allen appointed to spearhead Proximagen's licensing drive
Monday 02 February 2009
Peter Allen will be named as the new non-executive chairman of Proximagen Neuroscience this morning in a move that the group hopes will spearhead its consolidation of parts of the biotech industry.
Mr Allen has been appointed to the boards of several companies in the biotech industry in recent years. He is currently the non-executive chairman of the London-listed ProStrakan and the private group, Chroma.
Mr Allen has also helped to manage the sale of two other biotech groups. He is the finance director of Abacus, which was sold to Avent of the US last month and was a non-executive director of Acambis for a brief period last year, before it was sold to the pharmaceutical giant Sanofi-Aventis.
It is this experience that Proximagen will be hoping to tap as it seeks new merger, acquisition and licensing deals of its own. "I am delighted that Peter has chosen to join our board," Proximagen's chief executive Ken Mulvany. "He brings considerable relevant experience to Proximagen, particularly from within the biopharma and merger and acquisitions arena."
Proximagen, which specialises in finding treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's, has previously stated that it is actively trying to find acquisition targets. Mr Mulvany said in August, at the time of the group's interim results, that Proximagen "is well positioned to continue investment in our pipeline and exploit commercial opportunities as they arise".
Proximagen has seen its share price rise by nearly 40 per cent over the past 12 months and was picked as a stock tip at the start of 2008 by The Independent.
The group benefited last year by signing several agreements with other companies that it hopes will lead to substantial several milestone payments. In July, the group struck a $232m (£160m) licensing deal with Upsher-Smith, and, earlier in the year, the company penned a partnership agreement with Boehringer Ingelheim.
"Proximagen is operating in a very exciting scientific area and the company is well positioned in terms of the collaborations it has already signed and its financial standing," said Mr Allen.
- 1 Snoop Dogg and Jared Leto buy a stake in Reddit as A-list invests $50m
- 2 Prince held a Facebook Q&A and this is the only question he answered
- 3 Car tax disc changes: Two days to go - and they affect you much more than just not displaying a piece of paper
- 4 Now we know whose fault it is if you end up being murdered in Thailand
- 5 35,000 walrus gather ashore on north-west Alaska beach 'for a rest'
Snoop Dogg and Jared Leto buy a stake in Reddit as A-list invests $50m
Five-year-old Iris Grace is raising awareness of autism through her extraordinary paintings
Car tax disc changes: Five facts you never knew about your (almost obsolete) tax disc
The Aral Sea: Nasa pictures show how what was once the fourth largest lake in the world has become almost completely dry
Brad Pitt, on the moment he completely lost his temper with Clint Eastwood's son
Exclusive: 'Putin's Russia has been my biggest regret,' says Nato's outgoing Secretary General
The Osborne Ultimatum: Chancellor’s benefits freeze bombshell will affect ten million households
There’s no excuse for Dave Lee Travis’s behaviour, but we need to keep a sense of proportion
Should gay sex be illegal? 16% of Britons think so
Mark Reckless becomes second Tory MP to defect to Ukip in a month
Benefits 'smart cards' plan revealed by Iain Duncan Smith to stop claimants spending welfare money on alcohol
- < Previous
- Next >
iJobs Money & Business
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...
NEGOTIABLE: Austen Lloyd: TRUST ACCOUNTANT - KENTIf you are a Chartered Accou...
£18000 - £20000 per annum + OTE £30000: SThree: SThree are a global FTSE 250 b...
Highly Competitive Salary: Austen Lloyd: CITY - Law Costs Draftsperson - NICHE...